Skip to main
VERV
VERV logo

Verve Therapeutics (VERV) Stock Forecast & Price Target

Verve Therapeutics (VERV) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 8%

Bulls say

Verve Therapeutics, Inc. is positioned to revolutionize the treatment of cardiovascular disease through its novel gene-editing medicines, reflecting a paradigm shift from chronic to single-course therapies that promise enhanced patient adherence and lower healthcare costs. The company holds a strong balance sheet with $540 million in cash, providing a financial runway into mid-2027, which supports its ongoing research and development efforts in promising pipelines such as PCSK9, ANGPTL3, and LPA. Additionally, the recent licensing agreement with BEAM, providing access to advanced base editing technology, exemplifies the growing pharmaceutical interest in gene editing and positions Verve favorably within the competitive landscape.

Bears say

Verve Therapeutics Inc reported a net loss of $0.58 per share in its 4Q24 earnings, with a projected full-year 2025 net loss of $2.38 per share, indicating ongoing financial challenges and a non-revenue generating status. The company's early-stage programs and the lack of imminent catalysts raise concerns about its ability to advance candidates through clinical assessments, alongside significant regulatory hurdles associated with gene-editing technologies for cardiovascular disease. Additionally, investors face speculative risks related to stock price volatility and potential dilution, further complicating the outlook for Verve Therapeutics's stock.

Verve Therapeutics (VERV) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verve Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verve Therapeutics (VERV) Forecast

Analysts have given Verve Therapeutics (VERV) a Hold based on their latest research and market trends.

According to 13 analysts, Verve Therapeutics (VERV) has a Hold consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verve Therapeutics (VERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.